EYPT Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -357.26% compared to EyePoint Pharmaceuticals's net margin of -49.65%. EyePoint Pharmaceuticals's return on equity of -50.34% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

EyePoint Pharmaceuticals has a consensus price target of $33.00, signalling upside risk potential of 352.06%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 44.9%. Given that EyePoint Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe EyePoint Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

EyePoint Pharmaceuticals has a beta of 1.581, which suggesting that the stock is 58.087% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

EyePoint Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

EyePoint Pharmaceuticals quarterly revenues are $11.6M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. EyePoint Pharmaceuticals's net income of -$41.4M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, EyePoint Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Pharmaceuticals is 9.50x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Ocugen has a net margin of -357.26% compared to EyePoint Pharmaceuticals's net margin of -1816.75%. EyePoint Pharmaceuticals's return on equity of -50.34% beat Ocugen's return on equity of -171.04%.

EyePoint Pharmaceuticals has a consensus price target of $33.00, signalling upside risk potential of 352.06%. On the other hand Ocugen has an analysts' consensus of $6.75 which suggests that it could grow by 782.35%. Given that Ocugen has higher upside potential than EyePoint Pharmaceuticals, analysts believe Ocugen is more attractive than EyePoint Pharmaceuticals.

EyePoint Pharmaceuticals has a beta of 1.581, which suggesting that the stock is 58.087% more volatile than S&P 500. In comparison Ocugen has a beta of 4.214, suggesting its more volatile than the S&P 500 by 321.428%.

EyePoint Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Pharmaceuticals pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.

EyePoint Pharmaceuticals quarterly revenues are $11.6M, which are larger than Ocugen quarterly revenues of $764K. EyePoint Pharmaceuticals's net income of -$41.4M is lower than Ocugen's net income of -$13.9M. Notably, EyePoint Pharmaceuticals's price-to-earnings ratio is -- while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Pharmaceuticals is 9.50x versus 51.12x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -357.26% compared to EyePoint Pharmaceuticals's net margin of --. EyePoint Pharmaceuticals's return on equity of -50.34% beat Palatin Technologies's return on equity of --.

EyePoint Pharmaceuticals has a consensus price target of $33.00, signalling upside risk potential of 352.06%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 3112.48%. Given that Palatin Technologies has higher upside potential than EyePoint Pharmaceuticals, analysts believe Palatin Technologies is more attractive than EyePoint Pharmaceuticals.

EyePoint Pharmaceuticals has a beta of 1.581, which suggesting that the stock is 58.087% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

EyePoint Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. EyePoint Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

EyePoint Pharmaceuticals quarterly revenues are $11.6M, which are larger than Palatin Technologies quarterly revenues of --. EyePoint Pharmaceuticals's net income of -$41.4M is higher than Palatin Technologies's net income of --. Notably, EyePoint Pharmaceuticals's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Pharmaceuticals is 9.50x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -357.26% compared to EyePoint Pharmaceuticals's net margin of 26.7%. EyePoint Pharmaceuticals's return on equity of -50.34% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

EyePoint Pharmaceuticals has a consensus price target of $33.00, signalling upside risk potential of 352.06%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $802.21 which suggests that it could grow by 32.46%. Given that EyePoint Pharmaceuticals has higher upside potential than Regeneron Pharmaceuticals, analysts believe EyePoint Pharmaceuticals is more attractive than Regeneron Pharmaceuticals.

EyePoint Pharmaceuticals has a beta of 1.581, which suggesting that the stock is 58.087% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.331%.

EyePoint Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.15% to investors and pays a quarterly dividend of $0.88 per share. EyePoint Pharmaceuticals pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

EyePoint Pharmaceuticals quarterly revenues are $11.6M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. EyePoint Pharmaceuticals's net income of -$41.4M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, EyePoint Pharmaceuticals's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 15.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for EyePoint Pharmaceuticals is 9.50x versus 4.91x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.